Review



fab c terminal domain  (Merck & Co)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Merck & Co fab c terminal domain
    Pharmacological approaches currently under development against PCSK9.
    Fab C Terminal Domain, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fab c terminal domain/product/Merck & Co
    Average 90 stars, based on 1 article reviews
    fab c terminal domain - by Bioz Stars, 2026-06
    90/100 stars

    Images

    1) Product Images from "Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases"

    Article Title: Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases

    Journal: Scientifica

    doi: 10.6064/2012/927352

    Pharmacological approaches currently under development against PCSK9.
    Figure Legend Snippet: Pharmacological approaches currently under development against PCSK9.

    Techniques Used: Binding Assay



    Similar Products

    fab c terminal domain  (Merck & Co)
    90
    Merck & Co fab c terminal domain
    Pharmacological approaches currently under development against PCSK9.
    Fab C Terminal Domain, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fab c terminal domain/product/Merck & Co
    Average 90 stars, based on 1 article reviews
    fab c terminal domain - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Pharmacological approaches currently under development against PCSK9.

    Journal: Scientifica

    Article Title: Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases

    doi: 10.6064/2012/927352

    Figure Lengend Snippet: Pharmacological approaches currently under development against PCSK9.

    Article Snippet: Fab to C terminal domain , 1G08 , Merck Research Laboratories , [ ] .

    Techniques: Binding Assay